New research led by NYU Langone Medical Center examines what happens when a patient with multiple sclerosis (MS) who is clinically stable stops taking his or her medication.
The international, multi-site study found almost 40 percent of patients had some disease activity return when they stopped taking their meds. The findings were presented at the American Academy of Neurology annual meeting, held April 18-25 in Washington, D.C.
“Despite long periods of disease stability while taking medication, we found a large minority of patients who stopped experienced relapses or disability progression,” says lead study author Ilya Kister, MD, an assistant professor of neurology at the NYU Langone Multiple Sclerosis Comprehensive Care Center. “We need to identify situations when it is safe for patients with MS to stop taking these medications.”
Little is known about MS disease progression after first-line, disease-modifying therapies are discontinued in clinically-stable patients.
For the study, Dr. Kister and colleagues prospectively studied 181 patients from the global observational MSBase Registry, examining MS relapse rates and disability progression rates in patients who stopped taking disease-modifying therapy.
Patients in the study were ages 40 and older, had experienced no relapses and reported stable disability progression (measured by EDSS scores) for at least 5 years, and had been taking medication for at least 3 years. Once medications were ceased, patients were followed for at least three years.
After discontinuing medication, 24 percent of patients experienced a clinician-reported relapse, 32 percent sustained three-month disability progression, and 10.6 percent of patients recorded both relapses and disability progression.
Researchers found 77 patients—or 42 percent—restarted medication after a median of 22 months. Restarting medication was associated with a 59 percent risk reduction of disability progression.
More than 2.3 million people worldwide are affected by MS, according to the National Multiple Sclerosis Society (NMSS). The unpredictable disease affects the central nervous system, causing disability that can range in severity, with symptoms including muscle weakness, pain, difficulty with coordination and balance, partial or complete paralysis, tremors and hearing and vision loss.
Medication can help to manage attacks, reduce symptoms, and slow the progression of multiple sclerosis. According to the NMSS, some people stop taking disease-modifying medication for reasons including side effects, perceptions they’re not feeling better or because they still experience exacerbations, or insurance purposes.
“Decisions regarding stopping disease-modifying therapy may have implications for short and long-term prognosis. We know a lot about what happens when therapy is started, but we know very little about what happens when therapy is stopped,” says Dr. Kister.
Dr. Kister and colleagues call for a randomized trial of discontinuation of disease-modifying therapy to provide more evidence of when exactly it might be safe for patients to stop taking their medications.
In addition to Dr. Kister, the authors on this study were: Tim Spelman, Raed Alroughani, Jeannette Lechner-Scott, Helmut Butzkueven, Pierre Duquette, Francois Grand’Maison, Mark Slee, Alessandra Lugaresi, Michael Barnett, Pierre Grammond, Gerardo Iuliano, Raymond Hupperts, Maria Trojano, and Joseph Herbert on behalf of the MSBase Study Group.
[P5.192] ‘Doctor, can I stop my medicine?’ Analysis of disease course after stopping disease-modifying therapy in stable MS patients
American Academy of Neurology annual meeting, Washington, D.C.
Date: Wednesday, April 22, 2015
Session: P5: Poster Session V: MS and CNS Inflammatory Diseases: MS Disease Course, Activity, Progression, Cognition, and Quality of Life (2:00PM-6:30PM)